Naftopidil
Naftopidil is an inhibitor of α1-adrenergic receptors that is clinically used to improve lower urinary tract symptoms in subjects with benign prostatic hyperplasia (BPH). In clinical trials, naftopidil improves nocturnal polyuria. Naftopidil improves bladder capacity through both its effect on adrenergic signaling as well as inhibition of c-fiber afferent nerves. Additionally, this compound inhibits collagen-induced Ca2+ mobilization and platelet aggregation in vitro, exhibiting potential anti-platelet benefit.
References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18947926
| Cas No. |
57149-07-2 |
|---|---|
| Purity |
≥98% |
| Formula |
C24H28N2O3 |
| Formula Wt. |
392.49 |
| IUPAC Name |
1-[4-(2-methoxyphenyl)piperazin-1-yl]-3-naphthalen-1-yloxypropan-2-ol |
| Melting Point |
209.0 – 212.0 |
| Appearance |
White Crystal Powder |
Castiglione F, Benigni F, Briganti A, et al. Naftopidil for the treatment of benign prostate hyperplasia: a systematic review. Curr Med Res Opin. 2013 Dec 18. [Epub ahead of print]. PMID: 24188134.
Yokoyama O, Aoki Y, Tsujimura A, et al. α(1)-adrenoceptor blocker naftopidil improves sleep disturbance with reduction in nocturnal urine volume. World J Urol. 2011 Apr;29(2):233-8. PMID: 20387069.
Yokoyama O, Yusup A, Oyama N, et al. Improvement of bladder storage function by alpha1-blocker depends on the suppression of C-fiber afferent activity in rats. Neurourol Urodyn. 2006;25(5):461-7. PMID: 16673377.
Alarayyed NA, Cooper MB, Prichard BN, et al. In vitro adrenaline and collagen-induced mobilization of platelet calcium and its inhibition by naftopidil, doxazosin and nifedipine. Br J Clin Pharmacol. 1997 Apr;43(4):415-20. PMID: 9146854.
